MeSH term
Frequency | Condition_Probility | Animals | 10 | 0.0 |
Humans | 42 | 0.0 |
Acute Disease | 7 | 0.0 |
Adult | 7 | 0.0 |
Aged | 5 | 0.0 |
*Chromosomal Proteins, Non-Histone | 14 | 6.0 |
Female | 11 | 0.0 |
*Gene Expression Profiling | 3 | 0.0 |
Leukemia, Myeloid/*genetics | 4 | 2.0 |
Male | 12 | 0.0 |
Middle Aged | 11 | 0.0 |
RNA/metabolism | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 30 | 0.0 |
Translocation, Genetic | 4 | 0.0 |
Hela Cells | 9 | 0.0 |
Protein Binding | 3 | 0.0 |
Recombinant Fusion Proteins/metabolism | 3 | 0.0 |
Cell Line | 5 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Gene Expression Regulation | 3 | 0.0 |
Mice | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Tumor Cells, Cultured | 5 | 0.0 |
*Chromosome Deletion | 2 | 0.0 |
Genetic Markers | 3 | 0.0 |
*Antigens, Nuclear | 3 | 2.0 |
Binding Sites | 4 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
*Exons | 2 | 0.0 |
*Nuclear Matrix-Associated Proteins | 3 | 21.0 |
Nuclear Proteins/metabolism | 3 | 0.0 |
Oocytes/physiology | 2 | 1.0 |
RNA-Binding Proteins/*metabolism | 2 | 2.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
*Ribonucleoproteins | 2 | 5.0 |
Xenopus laevis | 2 | 0.0 |
Cell Cycle | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 15 | 0.0 |
Transcription, Genetic | 4 | 0.0 |
Base Sequence | 6 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
DNA, Complementary | 3 | 0.0 |
Molecular Sequence Data | 10 | 0.0 |
Disease Progression | 2 | 0.0 |
Oncogene Proteins/*metabolism | 5 | 5.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Ataxia Telangiectasia/metabolism | 2 | 40.0 |
Autoimmune Diseases/metabolism | 2 | 28.0 |
Chromosomal Proteins, Non-Histone/*chemistry/metabolism | 2 | 50.0 |
DNA/metabolism | 4 | 0.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Leukemia, Myelocytic, Acute/metabolism | 2 | 18.0 |
Mutagenesis | 2 | 0.0 |
Nuclear Magnetic Resonance, Biomolecular | 2 | 1.0 |
Oncogene Proteins/*chemistry/metabolism | 2 | 50.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Structural Homology, Protein | 2 | 9.0 |
Transcription Factors/chemistry | 2 | 6.0 |
Adolescent | 5 | 0.0 |
Autoantibodies/*blood | 2 | 0.0 |
Autoantigens/immunology | 2 | 1.0 |
Child | 5 | 0.0 |
Oncogene Proteins/*immunology | 4 | 80.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
Casein Kinase II | 2 | 1.0 |
DNA-Binding Proteins/*metabolism | 3 | 0.0 |
Phosphorylation | 3 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Chromosomes, Human, Pair 6/*genetics | 3 | 2.0 |
Karyotyping | 3 | 0.0 |
*Translocation, Genetic | 5 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Autoantigens/*metabolism | 2 | 8.0 |
DNA Probes | 2 | 0.0 |
Child, Preschool | 4 | 0.0 |
Infant | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Polymerase Chain Reaction | 3 | 0.0 |
*Chromosomes, Human, Pair 6 | 2 | 0.0 |
Exons | 2 | 0.0 |
*Oncogenes | 3 | 0.0 |
Chromosomes, Human, Pair 6 | 2 | 1.0 |
Chromosomes, Human, Pair 9 | 2 | 1.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Proteins/genetics/metabolism | 2 | 1.0 |
Comparative Study | 3 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Gene Expression Regulation, Leukemic | 2 | 2.0 |
Aged, 80 and over | 2 | 0.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
